Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (APYX) delivers innovative plasma-based energy systems for surgical and cosmetic applications. This news hub provides investors and medical professionals with timely updates on regulatory developments, product innovations, and strategic partnerships driving advancements in electrosurgical technology.
Access authoritative reporting on APYX's Advanced Energy segment developments, including Renuvion® system enhancements, and OEM manufacturing collaborations. Track financial performance updates, clinical study results, and market expansion initiatives critical to evaluating the company's position in medical device innovation.
Our curated news collection features earnings announcements, FDA clearances, research publications, and executive leadership changes. Stay informed about helium plasma technology applications in dermatology and general surgery through verified sources, maintained for accuracy and relevance.
Bookmark this page for streamlined access to APYX's evolving corporate narrative. Combine real-time updates with historical context to better understand this pioneer in energy-based surgical solutions.
Apyx Medical (NASDAQ: APYX), manufacturer of proprietary helium plasma and radiofrequency technology Renuvion®, has scheduled its first quarter fiscal year 2025 financial results release for May 8, 2025, before market open.
The company will host a conference call at 8:00 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (800-717-1738 for domestic, 646-307-1865 for international) using access code 63341, or through the company's webcast link and Investor Relations website section.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgical markets. The company's products are supported by over 90 clinical publications.
Renuvion, manufactured by Apyx Medical (NASDAQ: APYX), has won the 2025 NewBeauty Award for 'Best Minimally Invasive Skin Tightener.' The technology is the first and only FDA-cleared device for use after liposuction in body contouring treatments.
The recognition comes as consumer searches for 'sagging skin' increased by 168.7% in 2024. Renuvion's effectiveness is backed by over 90 evidence-based clinical publications, delivering long-lasting results from a single treatment. The technology combines helium plasma and radiofrequency platform technology for skin tightening and has gained widespread acceptance among plastic surgeons and consumers globally.
According to an independent survey by Wakefield Research, 4 out of 5 board-certified or eligible cosmetic and plastic surgeons in the US consider Renuvion the #1 trusted body contouring technology. The NewBeauty Awards, a leading beauty industry program, selected winners after extensive testing and consultation with board-certified doctors and medical experts.
Apyx Medical (NASDAQ:APYX) reported Q4 2024 financial results with total revenue of $14.2 million, showing mixed performance across segments. Advanced Energy revenue remained flat at $12.1 million, while OEM revenue decreased 16% to $2.1 million.
Key highlights include:
- Single-use handpiece shipments increased 5% overall and 20% in the U.S. year-over-year
- Net loss decreased 52% to $4.6 million compared to Q4 2023
- Adjusted EBITDA loss reduced by 53% to $2.2 million
- Implemented cost-saving restructuring, reducing U.S. workforce by 25%, targeting $4.3 million in annual savings
- Submitted 510(k) for AYON™ Body Contouring System ahead of schedule
For 2025 guidance, Apyx expects:
- Total revenue between $47.6-49.0 million
- Advanced Energy revenue of $39.6-41.0 million
- OEM revenue of approximately $8.0 million
- Operating expenses below $40.0 million
Apyx Medical (NASDAQ: APYX), developer of the proprietary Renuvion helium plasma and radiofrequency technology, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results release for March 13, 2025, before market opening.
The company will host a conference call at 8:30 a.m. Eastern Time on the same day, featuring a management discussion and Q&A session. Interested parties can join via phone (877-407-9039 for domestic, 201-689-8470 for international) using access code 13751519, or through the company's webcast link and Investor Relations website section.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. The company's products are supported by over 90 clinical documents and provide controlled heat tissue treatment.
Apyx Medical (NASDAQ:APYX) has released preliminary revenue results for Q4 and full year 2024. The company expects Q4 total revenue between $14.1-14.3 million, down 3-4% year-over-year, with Advanced Energy revenue of $12.0-12.2 million (flat YoY) and OEM revenue of $2.1 million (down 17% YoY).
For full year 2024, total revenue is projected at $48.0-48.2 million, an 8% decrease YoY. Advanced Energy segment expects $38.5-38.7 million (down 11% YoY), while OEM revenue shows growth at $9.5 million (up 6% YoY).
Notable improvements include 25% quarter-over-quarter growth in Advanced Energy sales during Q4, doubled generator unit sales in H2 2024 compared to H1, and strong U.S. single-use handpiece sales. The company plans to launch its new AYON™ Body Contouring System in H2 2025, pending FDA clearance, targeting the growing market for loose skin treatments, particularly driven by GLP-1 drug-related weight loss.
Apyx Medical (NASDAQ:APYX) has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, nearly 90 days ahead of schedule. The system is designed as an all-in-one platform for surgical body contouring procedures.
The initial submission includes multiple functionalities: infiltration, dual aspiration for simultaneous users, ultrasound-assisted liposuction, electrocoagulation for excess tissue removal, volume enhancement capabilities, and Renuvion treatment for loose and lax skin. The company plans to expand AYON's indications with an additional 510(k) submission later this year to include power-assisted liposuction.
Apyx Medical (NASDAQ:APYX) announced its participation in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, in New York. President and CEO Charlie Goodwin and CFO Matt Hill will conduct a fireside chat at 4:00pm ET and meet with investors throughout the day. The chat will be available via live webcast and replay on the company's investor relations website.
Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology marketed as Renuvion® for cosmetic surgery and J-Plasma® for hospital surgical markets. These products provide controlled heat delivery to tissue, supported by over 90 clinical documents.
Apyx Medical (NASDAQ:APYX) announced that President and CEO Charles Goodwin and CFO Matt Hill will attend the 15th Annual Craig-Hallum Alpha Select Conference. The event will take place on November 19, 2024, at the Sheraton NY Times Square Hotel in New York, NY, featuring 1x1 meetings format.
Apyx Medical is an advanced energy technology company specializing in Helium Plasma Platform Technology products, marketed as Renuvion in cosmetic surgery and J-Plasma in hospital surgical markets. Their technology provides surgeons with controlled heat tissue treatment capabilities, supported by over 90 clinical documents.
Apyx Medical (NASDAQ:APYX) has secured a $7 million registered direct offering through a definitive purchase agreement with Nantahala Capital. The offering includes 3,000,000 shares of common stock at $1.18 per share and pre-funded warrants for up to 2,934,690 shares at $1.179 per warrant. The purchase price was calculated using the average closing price over five trading days prior to November 7, 2024. The company plans to use the proceeds for working capital and general corporate purposes. The offering closed on November 8, 2024, with no placement agent involved.
Apyx Medical reported Q3 2024 financial results with total revenue of $11.5 million, down 4% year-over-year. The company's Advanced Energy segment decreased 6% to $9.3 million, while OEM revenue increased 3% to $2.2 million. Despite overall decline, single-use handpiece revenue grew 9% overall and 15% in the U.S. The company secured $7.0 million through a registered direct offering and implemented cost-saving measures, including a 25% reduction in U.S. workforce expected to save $4.3 million annually. Updated 2024 guidance projects total revenue of $46.6-47.6 million, representing a 9-11% decrease from 2023, with net loss expected at approximately $25.0 million.
